These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 23594368)

  • 21. NF-E2-mediated enhancement of megakaryocytic differentiation and platelet production in vitro and in vivo.
    Fock EL; Yan F; Pan S; Chong BH
    Exp Hematol; 2008 Jan; 36(1):78-92. PubMed ID: 17923245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs.
    Nishimura S; Nagasaki M; Kunishima S; Sawaguchi A; Sakata A; Sakaguchi H; Ohmori T; Manabe I; Italiano JE; Ryu T; Takayama N; Komuro I; Kadowaki T; Eto K; Nagai R
    J Cell Biol; 2015 May; 209(3):453-66. PubMed ID: 25963822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling.
    Lebois M; Dowling MR; Gangatirkar P; Hodgkin PD; Kile BT; Alexander WS; Josefsson EC
    J Thromb Haemost; 2016 Sep; 14(9):1882-7. PubMed ID: 27344013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production.
    Abraham M; Weiss ID; Wald H; Wald O; Nagler A; Beider K; Eizenberg O; Peled A
    Br J Haematol; 2013 Oct; 163(2):248-59. PubMed ID: 23906028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes.
    Liu ZJ; Italiano J; Ferrer-Marin F; Gutti R; Bailey M; Poterjoy B; Rimsza L; Sola-Visner M
    Blood; 2011 Apr; 117(15):4106-17. PubMed ID: 21304100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of platelet number and regulation of thrombopoiesis.
    Kaushansky K
    Hematology Am Soc Hematol Educ Program; 2009; ():147-52. PubMed ID: 20008193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional characterization of hNUDC as a novel accumulator that specifically acts on in vitro megakaryocytopoiesis and in vivo platelet production.
    Wei MX; Yang Y; Ge YC; Xu P
    J Cell Biochem; 2006 May; 98(2):429-39. PubMed ID: 16440315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis.
    Fukushima-Shintani M; Suzuki K; Iwatsuki Y; Abe M; Sugasawa K; Hirayama F; Kawasaki T
    Exp Hematol; 2008 Oct; 36(10):1337-42. PubMed ID: 18619724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Megakaryocytopoiesis in vitro: from the stem cells' perspective.
    Cardier JE; Foster DC; Lok S; Jacobsen SE; Murphy MJ
    Stem Cells; 1996; 14 Suppl 1():163-72. PubMed ID: 11012217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Romiplostim: a second-generation thrombopoietin agonist.
    Cohn CS; Bussel JB
    Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developmental differences between newborn and adult mice in response to romiplostim.
    Sparger KA; Ramsey H; Lorenz V; Liu ZJ; Feldman HA; Li N; Laforest T; Sola-Visner MC
    Platelets; 2018 Jun; 29(4):365-372. PubMed ID: 28548028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo platelet production from mature megakaryocytes: does platelet release occur via proplatelets?
    Kosaki G
    Int J Hematol; 2005 Apr; 81(3):208-19. PubMed ID: 15814332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
    Matsuki E; Miyakawa Y; Yamane A; Okamoto S
    Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.
    Bender M; Giannini S; Grozovsky R; Jönsson T; Christensen H; Pluthero FG; Ko A; Mullally A; Kahr WH; Hoffmeister KM; Falet H
    Blood; 2015 Feb; 125(6):1014-24. PubMed ID: 25468568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.
    Meyer SC; Keller MD; Woods BA; LaFave LM; Bastian L; Kleppe M; Bhagwat N; Marubayashi S; Levine RL
    Blood; 2014 Oct; 124(14):2280-4. PubMed ID: 25115888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
    Newland A
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation.
    Nagahisa H; Nagata Y; Ohnuki T; Osada M; Nagasawa T; Abe T; Todokoro K
    Blood; 1996 Feb; 87(4):1309-16. PubMed ID: 8608219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologic role of TPO in thrombopoiesis.
    Miyazaki H
    Stem Cells; 1996; 14 Suppl 1():133-8. PubMed ID: 11012213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical use of thrombopoietin (c-Mpl Ligand)].
    Borota R; Borota J; Belić A; Gebauer E; Stefanović N
    Med Pregl; 1998; 51(11-12):501-8. PubMed ID: 10081270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.